scholarly article | Q13442814 |
P50 | author | Daniele Santini | Q37837892 |
Loretta D'Onofrio | Q89174437 | ||
Marianna Silletta | Q114405675 | ||
Olga Venditti | Q114405692 | ||
Giuseppe Tonini | Q37838300 | ||
Bruno Vincenzi | Q37838310 | ||
Anna Maria Frezza | Q51716240 | ||
Andrea Napolitano | Q30347581 | ||
P2860 | cites work | Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma | Q37099811 |
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. | Q37210960 | ||
Protein kinase A and TORC1 activate genes for ribosomal biogenesis by inactivating repressors encoded by Dot6 and its homolog Tod6. | Q37415934 | ||
Targeting the mTOR pathway using deforolimus in cancer therapy | Q37448927 | ||
Targeting sarcomas: novel biological agents and future perspectives | Q37622277 | ||
mTOR signaling and drug development in cancer | Q37710367 | ||
mTOR Mediated Anti-Cancer Drug Discovery | Q37771869 | ||
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. | Q53984577 | ||
ER stress inhibits mTORC2 and Akt signaling through GSK-3β-mediated phosphorylation of rictor. | Q54610967 | ||
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas | Q57571056 | ||
Ezrin mediates growth and survival in Ewing’s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway | Q58376176 | ||
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 | Q21145847 | ||
Ubiquitination regulates PTEN nuclear import and tumor suppression | Q24292946 | ||
Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis | Q24293735 | ||
Activation of mTORC2 by association with the ribosome | Q24294876 | ||
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 | ||
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton | Q24299873 | ||
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery | Q24302549 | ||
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action | Q24302566 | ||
Requirement of the mTOR kinase for the regulation of Maf1 phosphorylation and control of RNA polymerase III-dependent transcription in cancer cells | Q24303535 | ||
Identification of Protor as a novel Rictor-binding component of mTOR complex-2 | Q24303936 | ||
SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth | Q24309283 | ||
DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival | Q24311448 | ||
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1 | Q24315566 | ||
mTOR associates with TFIIIC, is found at tRNA and 5S rRNA genes, and targets their repressor Maf1 | Q24319851 | ||
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway | Q24337225 | ||
Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner | Q24337323 | ||
Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. | Q24540159 | ||
Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth | Q24603549 | ||
Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator | Q24609227 | ||
A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? | Q24629627 | ||
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology | Q24632651 | ||
mTOR regulates memory CD8 T-cell differentiation | Q24648624 | ||
Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray | Q24657451 | ||
The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study | Q36454797 | ||
Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors | Q36486421 | ||
Therapeutic targets: MTOR and related pathways | Q36592032 | ||
Targeted therapy for dermatofibrosarcoma protuberans | Q36718629 | ||
Gene expression profiling in sarcomas | Q36843032 | ||
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study | Q36856816 | ||
The biology behind mTOR inhibition in sarcoma | Q36927347 | ||
PTEN loss in the continuum of common cancers, rare syndromes and mouse models. | Q37856722 | ||
Temsirolimus in advanced leiomyosarcomas: patterns of response and correlation with the activation of the mammalian target of rapamycin pathway | Q38412112 | ||
Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma | Q38448504 | ||
Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models | Q39463504 | ||
Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin | Q39524587 | ||
MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration | Q39526077 | ||
Chromatin structure predicts epigenetic therapy responsiveness in sarcoma | Q39610375 | ||
Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma. | Q39624408 | ||
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. | Q39640530 | ||
mTOR binds to the promoters of RNA polymerase I- and III-transcribed genes | Q39758212 | ||
mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling | Q39765614 | ||
Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin | Q39827828 | ||
Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk | Q39924288 | ||
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway | Q40124442 | ||
Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif | Q40133024 | ||
Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma | Q40200306 | ||
The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor | Q40244438 | ||
Functional genomics identifies TOR-regulated genes that control growth and division | Q40277449 | ||
Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma | Q40417879 | ||
Alternative phospholipase D/mTOR survival signal in human breast cancer cells | Q40484574 | ||
Mechanism of action of the immunosuppressant rapamycin | Q40965429 | ||
SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo | Q41099411 | ||
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors | Q43052325 | ||
Rapamycin for Kaposi's sarcoma and graft-versus-host disease in bone marrow transplant recipient | Q43136394 | ||
Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa | Q43136879 | ||
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity | Q43211411 | ||
Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates | Q43237952 | ||
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor | Q43873032 | ||
Adjuvant chemotherapy in 2011 for patients with soft-tissue sarcoma | Q44882085 | ||
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies | Q45067792 | ||
Targeting the mammalian target of rapamycin in myxoid chondrosarcoma. | Q46338130 | ||
Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases | Q46385316 | ||
Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy | Q46834814 | ||
Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies | Q46894274 | ||
Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma | Q46973585 | ||
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. | Q51803667 | ||
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling | Q24672005 | ||
A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling | Q24678327 | ||
Crystal structure of the Gtr1p-Gtr2p complex reveals new insights into the amino acid-induced TORC1 activation | Q27671542 | ||
Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP | Q27732817 | ||
TSC2 mediates cellular energy response to control cell growth and survival | Q27860970 | ||
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors | Q28118852 | ||
Phosphatidic acid-mediated mitogenic activation of mTOR signaling | Q28208274 | ||
PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells | Q28237807 | ||
The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer | Q28244254 | ||
SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity | Q28262782 | ||
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1 | Q28276788 | ||
Autophagy and signaling: their role in cell survival and cell death | Q28278893 | ||
DNA hypermethylation status of multiple genes in soft tissue sarcomas | Q28279569 | ||
Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells | Q28305483 | ||
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB | Q28306356 | ||
Phosphoproteomic profiling of in vivo signaling in liver by the mammalian target of rapamycin complex 1 (mTORC1) | Q28478869 | ||
Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1 | Q28505561 | ||
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 | Q29614563 | ||
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E | Q29618009 | ||
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
Akt regulates growth by directly phosphorylating Tsc2 | Q29620397 | ||
mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway | Q30425628 | ||
mTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion | Q30499352 | ||
EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors | Q33273472 | ||
Ribosomal S6 kinase signaling and the control of translation | Q33783527 | ||
E2F1 regulates cellular growth by mTORC1 signaling | Q33808832 | ||
Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures | Q33873775 | ||
Amplification of the angiogenic signal through the activation of the TSC/mTOR/HIF axis by the KSHV vGPCR in Kaposi's sarcoma | Q33895137 | ||
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. | Q33928657 | ||
Regulation of mTORC1 signaling by pH | Q33955047 | ||
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial | Q34041573 | ||
Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. | Q34063643 | ||
Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway | Q34085728 | ||
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation | Q34109986 | ||
PDGFRA activating mutations in gastrointestinal stromal tumors. | Q34169772 | ||
Tuberous sclerosis: from tubers to mTOR. | Q34173640 | ||
Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size | Q34176565 | ||
Clinical pharmacokinetics of sirolimus | Q34347243 | ||
Everolimus for advanced pancreatic neuroendocrine tumors. | Q34399809 | ||
Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release | Q34452585 | ||
The Pim protein kinases regulate energy metabolism and cell growth | Q34490450 | ||
Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus | Q34532986 | ||
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules | Q34610473 | ||
A continuum model for tumour suppression | Q34631552 | ||
miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas | Q34700668 | ||
Phosphatidylserine is a critical modulator for Akt activation | Q34712409 | ||
Phospholipase D1 is an effector of Rheb in the mTOR pathway. | Q34786317 | ||
mTOR complex 2 targets Akt for proteasomal degradation via phosphorylation at the hydrophobic motif. | Q34800160 | ||
IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. | Q34836259 | ||
Control of mTORC1 signaling by the Opitz syndrome protein MID1. | Q35008479 | ||
Relieving autophagy and 4EBP1 from rapamycin resistance | Q35096637 | ||
PI3Kγ mediates kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. | Q35207596 | ||
Mechanisms of sarcoma development | Q35210018 | ||
Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway | Q35213308 | ||
Phosphatidic acid activates mammalian target of rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an allosteric effect | Q35313512 | ||
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling | Q35370616 | ||
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR | Q35613890 | ||
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. | Q35751042 | ||
A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). | Q35854468 | ||
Advances in sarcoma genomics and new therapeutic targets | Q35993346 | ||
Oncogenic PI3K deregulates transcription and translation | Q36337966 | ||
Oncogenic PI3K and its role in cancer | Q36343294 | ||
mTOR and cancer: reason for dancing at the crossroads? | Q36344439 | ||
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis | Q36384467 | ||
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | sirolimus | Q32089 |
P304 | page(s) | 1685-1705 | |
P577 | publication date | 2011-10-20 | |
P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
P1476 | title | Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside | |
P478 | volume | 20 |